#BEGIN_DRUGCARD DB01955

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
110-63-4

# ChEBI_ID:
41189

# Chemical_Formula:
C4H10O2

# Chemical_IUPAC_Name:
butane-1,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2248224

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
11150358	Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA: Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med. 2001 Jan 11;344(2):87-94.
12892832	Satta R, Dimitrijevic N, Manev H: Drosophila metabolize 1,4-butanediol into gamma-hydroxybutyric acid in vivo. Eur J Pharmacol. 2003 Jul 25;473(2-3):149-52.
6717752	Poldrugo F, Snead OC 3rd: 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions. Neuropharmacology. 1984 Jan;23(1):109-113.

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.83

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L (at 20 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1,4-Butanediol

# HET_ID:
BU1

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2

# InChI_Key:
InChIKey=WERYXYBDKMZEQL-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1955

# Mechanism_Of_Action:
Not Available

# Melting_Point:
20.1 °C

# Molecular_Weight_Avg:
90.121

# Molecular_Weight_Mono:
90.068079564

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1X9D

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.63

# Predicted_LogS:
0.87

# Predicted_Water_Solubility:
6.75e+02 g/l

# Primary_Accession_No:
DB01955

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
8064

# PubChem_Substance_ID:
46506248

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00771

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OCCCCO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:39 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/1,4-Butanediol

# pKa_Isoelectric_Point:
14.5 (at 25 °C)

# Drug_Target_1_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
single-pass type II membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MAN1B1

# Drug_Target_1_GenBank_ID_Gene:
AF148509

# Drug_Target_1_GenBank_ID_Protein:
6066222

# Drug_Target_1_GeneCard_ID:
MAN1B1

# Drug_Target_1_Gene_Name:
MAN1B1

# Drug_Target_1_Gene_Sequence:
>2100 bp
ATGGCTGCCTGCGAGGGCAGGAGAAGCGGAGCTCTCGGTTCCTCTCAGTCGGACTTCCTG
ACGCCGCCAGTGGGCGGGGCCCCTTGGGCCGTCGCCACCACTGTAGTCATGTACCCACCG
CCGCCGCCGCCGCCTCATCGGGACTTCATCTCGGTGACGCTGAGCTTTGGCGAGAGCTAT
GACAACAGCAAGAGTTGGCGGCGGCGCTCGTGCTGGAGGAAATGGAAGCAACTGTCGAGA
TTGCAGCGGAATATGATTCTCTTCCTCCTTGCCTTTCTGCTTTTCTGTGGACTCCTCTTC
TACATCAACTTGGCTGACCATTGGAAAGCTCTGGCTTTCAGGCTAGAGGAAGAGCAGAAG
ATGAGGCCAGAAATTGCTGGGTTAAAACCAGCAAATCCACCCGTCTTACCAGCTCCTCAG
AAGGCGGACACCGACCCTGAGAACTTACCTGAGATTTCGTCACAGAAGACACAAAGACAC
ATCCAGCGGGGACCACCTCACCTGCAGATTAGACCCCCAAGCCAAGACCTGAAGGATGGG
ACCCAGGAGGAGGCCACAAAAAGGCAAGAAGCCCCTGTGGATCCCCGCCCGGAAGGAGAT
CCGCAGAGGACAGTCATCAGCTGGAGGGGAGCGGTGATCGAGCCTGAGCAGGGCACCGAG
CTCCCTTCAAGAAGAGCAGAAGTGCCCACCAAGCCTCCCCTGCCACCGGCCAGGACACAG
GGCACACCAGTGCATCTGAACTATCGCCAGAAGGGCGTGATTGACGTCTTCCTGCATGCA
TGGAAAGGATACCGCAAGTTTGCATGGGGCCATGACGAGCTGAAGCCTGTGTCCAGGTCC
TTCAGTGAGTGGTTTGGCCTCGGTCTCACACTGATCGACGCGCTGGACACCATGTGGATC
TTGGGTCTGAGGAAAGAATTTGAGGAAGCCAGGAAGTGGGTGTCGAAGAAGTTACACTTT
GAAAAGGACGTGGACGTCAACCTGTTTGAGAGCACGATCCGCATCCTGGGGGGGCTCCTG
AGTGCCTACCACCTGTCTGGGGACAGCCTCTTCCTGAGGAAAGCTGAGGATTTTGGAAAT
CGGCTAATGCCTGCCTTCAGAACACCATCCAAGATTCCTTACTCGGATGTGAACATCGGT
ACTGGAGTTGCCCACCCGCCACGGTGGACCTCCGACAGCACTGTGGCCGAGGTGACCAGC
ATTCAGCTGGAGTTCCGGGAGCTCTCCCGTCTCACAGGGGATAAGAAGTTTCAGGAGGCA
GTGGAGAAGGTGACACAGCACATCCACGGCCTGTCTGGGAAGAAGGATGGGCTGGTGCCC
ATGTTCATCAATACCCACAGTGGCCTCTTCACCCACCTGGGCGTATTCACGCTGGGCGCC
AGGGCCGACAGCTACTATGAGTACCTGCTGAAGCAGTGGATCCAGGGCGGGAAGCAGGAG
ACACAGCTGCTGGAAGACTACGTGGAAGCCATCGAGGGTGTCAGAACGCACCTGCTGCGG
CACTCCGAGCCCAGTAAGCTCACCTTTGTGGGGGAGCTTGCCCACGGCCGCTTCAGTGCC
AAGATGGACCACCTGGTGTGCTTCCTGCCAGGGACGCTGGCTCTGGGCGTCTACCACGGC
CTGCCCGCCAGCCACATGGAGCTGGCCCAGGAGCTCATGGAGACTTGTTACCAGATGAAC
CGGCAGATGGAGACGGGGCTGAGTCCCGAGATCGTGCACTTCAACCTTTACCCCCAGCCG
GGCCGTCGGGACGTGGAGGTCAAGCCAGCAGACAGGCACAACCTGCTGCGGCCAGAGACC
GTGGAGAGCCTGTTCTACCTGTACCGCGTCACAGGGGACCGCAAATACCAGGACTGGGGC
TGGGAGATTCTGCAGAGCTTCAGCCGATTCACACGGGTCCCCTCGGGTGGCTATTCTTCC
ATCAACAATGTCCAGGATCCTCAGAAGCCCGAGCCTAGGGACAAGATGGAGAGCTTCTTC
CTGGGGGAGACGCTCAAGTATCTGTTCTTGCTCTTCTCCGATGACCCAAACCTGCTCAGC
CTGGACGCCTACGTGTTCAACACCGAAGCCCACCCTCTGCCTATCTGGACCCCTGCCTAG

# Drug_Target_1_General_Function:
Involved in mannosyl-oligosaccharide 1,2-alpha-mannosidase activity

# Drug_Target_1_General_References:
10409699	Gonzalez DS, Karaveg K, Vandersall-Nairn AS, Lal A, Moremen KW: Identification, expression, and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis. J Biol Chem. 1999 Jul 23;274(30):21375-86.
10521544	Tremblay LO, Herscovics A: Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis. Glycobiology. 1999 Oct;9(10):1073-8.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_1_HGNC_ID:
HGNC:6823

# Drug_Target_1_HPRD_ID:
05068

# Drug_Target_1_ID:
2577

# Drug_Target_1_Locus:
9q34

# Drug_Target_1_Molecular_Weight:
79581

# Drug_Target_1_Name:
Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase

# Drug_Target_1_Number_of_Residues:
699

# Drug_Target_1_PDB_ID:
1X9D

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01532	Glyco_hydro_47

# Drug_Target_1_Protein_Sequence:
>Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase
MAACEGRRSGALGSSQSDFLTPPVGGAPWAVATTVVMYPPPPPPPHRDFISVTLSFGENY
DNSKSWRRRSCWRKWKQLSRLQRNMILFLLAFLLFCGLLFYINLADHWKALAFRLEEEQK
MRPEIAGLKPANPPVLPAPQKADTDPENLPEISSQKTQRHIQRGPPHLQIRPPSQDLKDG
TQEEATKRQEAPVDPRPEGDPQRTVISWRGAVIEPEQGTELPSRRAEVPTKPPLPPARTQ
GTPVHLNYRQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWI
LGLRKEFEEARKWVSKKLHFEKDVDVNLFESTIRILGGLLSAYHLSGDSLFLRKAEDFGN
RLMPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQEA
VEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYYEYLLKQWIQGGKQE
TQLLEDYVEAIEGVRTHLLRHSEPSKLTFVGELAHGRFSAKMDHLVCFLPGTLALGVYHG
LPASHMELAQELMETCYQMNRQMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLLRPET
VESLFYLYRVTGDRKYQDWGWEILQSFSRFTRVPSGGYSSINNVQDPQKPEPRDKMESFF
LGETLKYLFLLFSDDPNLLSLDAYVFNTEAHPLPIWTPA

# Drug_Target_1_Reaction:
Hydrolysis of the terminal 1,2-linked alpha-D-mannose residues in the oligo-mannose oligosaccharide Man9(GlcNAc)2 ALL_REAC (other) R05982(G) R06722(G)

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the maturation of Asn-linked oligosaccharides. Trim a single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2). The only product is the Man(8)GlcNAc(2) isomer B, the form lacking the middle-arm terminal alpha 1,2-mannose. It may be involved in glycoprotein quality control since it is important to target misfolded glycoproteins for degradation

# Drug_Target_1_SwissProt_ID:
Q9UKM7

# Drug_Target_1_SwissProt_Name:
MA1B1_HUMAN

# Drug_Target_1_Synonyms:
EC 3.2.1.113
ER alpha-1,2-mannosidase
Man9GlcNAc2-specific-processing alpha-mannosidase
Mannosidase alpha class 1B member 1

# Drug_Target_1_Theoretical_pI:
7.80

# Drug_Target_1_Transmembrane_Regions:
85-105

# Drug_Target_2_Cellular_Location:
Membrane
peripheral membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PLA2G2A

# Drug_Target_2_GenBank_ID_Gene:
M22430

# Drug_Target_2_GenBank_ID_Protein:
190889

# Drug_Target_2_GeneCard_ID:
PLA2G2A

# Drug_Target_2_Gene_Name:
PLA2G2A

# Drug_Target_2_Gene_Sequence:
>435 bp
ATGAAGACCCTCCTACTGTTGGCAGTGATCATGATCTTTGGCCTACTGCAGGCCCATGGG
AATTTGGTGAATTTCCACAGAATGATCAAGTTGACGACAGGAAAGGAAGCCGCACTCAGT
TATGGCTTCTACGGCTGCCACTGTGGCGTGGGTGGCAGAGGATCCCCCAAGGATGCAACG
GATCGCTGCTGTGTCACTCATGACTGTTGCTACAAACGTCTGGAGAAACGTGGATGTGGC
ACCAAATTTCTGAGCTACAAGTTTAGCAACTCGGGGAGCAGAATCACCTGTGCAAAACAG
GACTCCTGCAGAAGTCAACTGTGTGAGTGTGATAAGGCTGCTGCCACCTGTTTTGCTAGA
AACAAGACGACCTACAATAAAAAGTACCAGTACTATTCCAATAAACACTGCAGAGGGAGC
ACCCCTCGTTGCTGA

# Drug_Target_2_General_Function:
Involved in phospholipase A2 activity

# Drug_Target_2_General_References:
1948070	Scott DL, White SP, Browning JL, Rosa JJ, Gelb MH, Sigler PB: Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science. 1991 Nov 15;254(5034):1007-10.
2062381	Wery JP, Schevitz RW, Clawson DK, Bobbitt JL, Dow ER, Gamboa G, Goodson T Jr, Hermann RB, Kramer RM, McClure DB, et al.: Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 A resolution. Nature. 1991 Jul 4;352(6330):79-82.
2239446	Kramer RM, Johansen B, Hession C, Pepinsky RB: Structure and properties of a secretable phospholipase A2 from human platelets. Adv Exp Med Biol. 1990;275:35-53.
2775276	Kanda A, Ono T, Yoshida N, Tojo H, Okamoto M: The primary structure of a membrane-associated phospholipase A2 from human spleen. Biochem Biophys Res Commun. 1989 Aug 30;163(1):42-8.
2925608	Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J, Johnson LK: Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989 Apr 5;264(10):5335-8.
2925633	Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R, Pepinsky RB: Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem. 1989 Apr 5;264(10):5768-75.
3202859	Lai CY, Wada K: Phospholipase A2 from human synovial fluid: purification and structural homology to the placental enzyme. Biochem Biophys Res Commun. 1988 Dec 15;157(2):488-93.
3240982	Hara S, Kudo I, Matsuta K, Miyamoto T, Inoue K: Amino acid composition and NH2-terminal amino acid sequence of human phospholipase A2 purified from rheumatoid synovial fluid. J Biochem (Tokyo). 1988 Sep;104(3):326-8.
7664108	Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE, Hartley LW, Jones ND, Mihelich ED, et al.: Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458-65.
8399335	Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M: Purification and characterization of a phospholipase A2 from human ileal mucosa. Biochim Biophys Acta. 1993 Oct 13;1170(2):125-30.
9538252	Kitadokoro K, Hagishita S, Sato T, Ohtani M, Miki K: Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032. J Biochem (Tokyo). 1998 Apr;123(4):619-23.

# Drug_Target_2_HGNC_ID:
HGNC:9031

# Drug_Target_2_HPRD_ID:
01397

# Drug_Target_2_ID:
2981

# Drug_Target_2_Locus:
1p35

# Drug_Target_2_Molecular_Weight:
16083

# Drug_Target_2_Name:
Phospholipase A2, membrane associated

# Drug_Target_2_Number_of_Residues:
144

# Drug_Target_2_PDB_ID:
1DB4

# Drug_Target_2_Pathway:
Abciximab Pathway	SMP00265
Acetylsalicylic Acid Pathway	SMP00083
Bromfenac Pathway	SMP00102
Celecoxib Pathway	SMP00096
Cilostazol Pathway	SMP00263
Clopidogrel Pathway	SMP00260
Diclofenac Pathway	SMP00093
Diflunisal Pathway	SMP00289
Dipyridamole (Antiplatelet) Pathway	SMP00264
Eptifibatide Pathway	SMP00266
Etodolac Pathway	SMP00084
Ibuprofen Pathway	SMP00086
Indomethacin Pathway	SMP00104
Ketoprofen Pathway	SMP00085
Ketorolac Pathway	SMP00098
Mefanamic Acid Pathway	SMP00109
Meloxicam Pathway	SMP00106
Nabumetone Pathway	SMP00114
Naproxen Pathway	SMP00120
Oxaprozin Pathway	SMP00113
Piroxicam Pathway	SMP00077
Rofecoxib Pathway	SMP00087
Sulindac Pathway	SMP00094
Suprofen Pathway	SMP00101
Ticlopidine Pathway	SMP00261
Tirofiban Pathway	SMP00267
Valdecoxib Pathway	SMP00116

# Drug_Target_2_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_2_Protein_Sequence:
>Phospholipase A2, membrane associated precursor
MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDAT
DRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFAR
NKTTYNKKYQYYSNKHCRGSTPRC

# Drug_Target_2_Reaction:
phosphatidylcholine + H2O = 1-acylglycerophosphocholine + a carboxylate

# Drug_Target_2_Signals:
1-20

# Drug_Target_2_Specific_Function:
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides

# Drug_Target_2_SwissProt_ID:
P14555

# Drug_Target_2_SwissProt_Name:
PA2GA_HUMAN

# Drug_Target_2_Synonyms:
EC 3.1.1.4
GIIC sPLA2
Group IIA phospholipase A2
NPS-PLA2
Non-pancreatic secretory phospholipase A2
Phosphatidylcholine 2-acylhydrolase
Phospholipase A2, membrane associated precursor

# Drug_Target_2_Theoretical_pI:
9.51

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted

# Drug_Target_3_Chromosome_Location:
1

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AF189279

# Drug_Target_3_GenBank_ID_Protein:
7108923

# Drug_Target_3_GeneCard_ID:
PLA2G2E

# Drug_Target_3_Gene_Name:
PLA2G2E

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Involved in calcium ion binding

# Drug_Target_3_General_References:
10681567	Suzuki N, Ishizaki J, Yokota Y, Higashino K, Ono T, Ikeda M, Fujii N, Kawamoto K, Hanasaki K: Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem. 2000 Feb 25;275(8):5785-93.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.

# Drug_Target_3_HGNC_ID:
GNC:13414

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6270

# Drug_Target_3_Locus:
1p36.13

# Drug_Target_3_Molecular_Weight:
15988.5

# Drug_Target_3_Name:
Group IIE secretory phospholipase A2

# Drug_Target_3_Number_of_Residues:
142

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00068	Phospholip_A2_1

# Drug_Target_3_Protein_Sequence:
>Group IIE secretory phospholipase A2
MKSPHVLVFLCLLVALVTGNLVQFGVMIEKMTGKSALQYNDYGCYCGIGGSHWPVDQTDW
CCHAHDCCYGRLEKLGCEPKLEKYLFSVSERGIFCAGRTTCQRLTCECDKRAALCFRRNL
GTYNRKYAHYPNKLCTGPTPPC

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-19

# Drug_Target_3_Specific_Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2- acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids

# Drug_Target_3_SwissProt_ID:
Q9NZK7

# Drug_Target_3_SwissProt_Name:
PA2GE_HUMAN

# Drug_Target_3_Synonyms:
GIIE sPLA2
Phosphatidylcholine 2-acylhydrolase GIIE
sPLA(2)-IIE

# Drug_Target_3_Theoretical_pI:
8.28

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
L42023

# Drug_Target_4_GenBank_ID_Protein:
1574175

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
rsuA

# Drug_Target_4_Gene_Sequence:
>699 bp
TTATTTTACTAACTTTTCAATTTCACTTTGAGTTAATGGGCGGTATTCGCCTTCTTCTAA
GGATTCATCCAACACTACATCACCAATTTTCCAGCGATGTAATCCAACGACTTTATTCCC
AAGTGCGGCAAACATACGTTTTACTTGATGATAACGACCTTCAGAAATGGTCAGATTCAC
ATTGTAGTCATCTAAAATTTCTAATTTTGCTGGTTTAGTGGGCTCTTTTTCTCCGCGTAA
TAAAATGCCTTCTGCACAAGCTGCTGAATAATTTTCTTCTACGGGATCAGCTAATGTCAC
CAAATAGGTTTTTTCACAATGATGCTTTGGGGAAGTGATGCGATGTGACCATTGTCCATC
ATCGGTAAGCAATACGAGACCTGTCGTATCCACATCTAAGCGACCTGCGCTATGTAATTT
TCCAGCTAAAGGGTAATCAAAAAATTGATAAATTGTTGGATAGTCGCCGTCATCATTAGA
ACAAACACAGCCTTGTGGTTTATTCAACATAAAATACTGGCCTTCTTCGATCCAAGTTAA
TAATTCATCTTCAAAATAAATTTCGTCTTCTTGTGAAATTTGAACCGAACCACTTTTGAC
AATTTCACCGTTGATTTTTACCGCACTTTGGCGGATCGCTTTTGTTGCTTGAGAACGAGT
TAATCCCACATTTTCAGCAATAAATTTATCTAATCTCAT

# Drug_Target_4_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_4_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2344

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
26213

# Drug_Target_4_Name:
Ribosomal small subunit pseudouridine synthase A

# Drug_Target_4_Number_of_Residues:
232

# Drug_Target_4_PDB_ID:
1VIO

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00849	PseudoU_synth_2
PF01479	S4

# Drug_Target_4_Protein_Sequence:
>Ribosomal small subunit pseudouridine synthase A
MRLDKFIAENVGLTRSQATKAIRQSAVKINGEIVKSGSVQISQEDEIYFEDELLTWIEEG
QYFMLNKPQGCVCSNDDGDYPTIYQFFDYPLAGKLHSAGRLDVDTTGLVLLTDDGQWSHR
ITSPKHHCEKTYLVTLADPVEENYSAACAEGILLRGEKEPTKPAKLEILDDYNVNLTISE
GRYHQVKRMFAALGNKVVGLHRWKIGDVVLDESLEEGEYRPLTQSEIEKLVK

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Responsible for synthesis of pseudouridine from uracil- 516 in 16S ribosomal RNA

# Drug_Target_4_SwissProt_ID:
P45124

# Drug_Target_4_SwissProt_Name:
RSUA_HAEIN

# Drug_Target_4_Synonyms:
16S pseudouridine 516 synthase
16S pseudouridylate 516 synthase
EC 5.4.99.-
rRNA pseudouridylate synthase A
rRNA- uridine isomerase A

# Drug_Target_4_Theoretical_pI:
4.75

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Periplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X16909

# Drug_Target_5_GenBank_ID_Protein:
41993

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
mepA

# Drug_Target_5_Gene_Sequence:
>825 bp
ATGAATAAAACCGCGATTGCGCTGCTGGCTCTGCTTGCCAGTAGCGCCAGCCTGGCAGCG
ACGCCGTGGCAAAAAATAACCCAACCTGTGCCGGGTAGCGCACAATCGATAGGCAGTTTT
TCTAATGGCTGTATTGTCGGCGCTGACACGCTGCCGATACAGTCCGAACATTATCAGGTC
ATGCGTACCGATCAGCGTCGCTATTTCGGTCACCCGGATCTGGTGATGTTTATCCAGCGT
CTGAGTAGCCAGGTGAGCAATCTGGGCATGGGTACGGTGCTGATTGGCGATATGGGGATG
CCCGCTGGTGGGCGTTTCAACGGCGGTCATGCCAGCCACCAGACCGGACTGGATGTCGAT
ATCTTTCTGCAACTGCCGAAAACTCGCTGGACCTCCGCGCAGCTCTTGCGCCCGCAAGCA
CTGGACTTAGTTTCCCGCGACGGTAAACACGTTGTCTCCACGCTGTGGAAGCCAGAAATT
TTCAGCTTGATCAAACTCGCCGCCCAGGACAAAGACGTCACGCGCATTTTTGTTAATCCG
GCGATTAAACAACAACTTTGCCTTGATGCGGGCACCGATCGCGACTGGTTGCGCAAAGTG
CGACCCTGGTTCCAGCATCGCGCGCATATGCATGTACGATTACGTTGCCCTGCCGATAGT
CTGGAGTGTGAAGATCAACCTTTACCGCCATCAGGCGATGGTTGCGGGGCAGAACTGCAA
AGCTGGTTTGAACCTCCAAAACCGGGAACAACAAAGCCTGAGAAGAAGACACCGCCTCCG
TTGCCGCCTTCCTGCCAGGCGCTACTGGATGAGCACGTGATCTAA

# Drug_Target_5_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_5_General_References:
2187143	Keck W, van Leeuwen AM, Huber M, Goodell EW: Cloning and characterization of mepA, the structural gene of the penicillin-insensitive murein endopeptidase from Escherichia coli. Mol Microbiol. 1990 Feb;4(2):209-19.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
3677

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
30137

# Drug_Target_5_Name:
Penicillin-insensitive murein endopeptidase precursor

# Drug_Target_5_Number_of_Residues:
274

# Drug_Target_5_PDB_ID:
1TZP

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF03411	Peptidase_M74

# Drug_Target_5_Protein_Sequence:
>Penicillin-insensitive murein endopeptidase precursor
MNKTAIALLALLASSASLAATPWQKITQPVPGSAQSIGSFSNGCIVGADTLPIQSEHYQV
MRTDQRRYFGHPDLVMFIQRLSSQVSNLGMGTVLIGDMGMPAGGRFNGGHASHQTGLDVD
IFLQLPKTRWTSAQLLRPQALDLVSRDGKHVVSTLWKPEIFSLIKLAAQDKDVTRIFVNP
AIKQQLCLDAGTDRDWLRKVRPWFQHRAHMHVRLRCPADSLECEDQPLPPSGDGCGAELQ
SWFEPPKPGTTKPEKKTPPPLPPSCQALLDEHVI

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-19

# Drug_Target_5_Specific_Function:
Involved in the removal of murein from the sacculus. May also facilitate integration of nascent murein strands into the sacculus by cleaving the peptide bonds between neighboring strands in mature murein

# Drug_Target_5_SwissProt_ID:
P0C0T5

# Drug_Target_5_SwissProt_Name:
MEPA_ECOLI

# Drug_Target_5_Synonyms:
D-alanyl-D-alanine-endopeptidase
DD-endopeptidase
EC 3.4.24.-

# Drug_Target_5_Theoretical_pI:
8.40

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB01955
